NEW YORK--(BUSINESS WIRE)--Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced the availability of its enriched solution for risk-based monitoring (RBM) of clinical trial sites. The company’s previously announced acquisition of Patient Profiles, an early-stage software company focused on improving clinical trial data quality, broadens Medidata’s best-in-class technology for RBM, a proven methodology for reducing trial costs while providing a higher level of clinical data accuracy and quality.
“Working with Patient Profiles has given Biotie Therapies Inc. the ability to understand complex interrelated datasets and target our monitoring needs, enhancing the quality of our data reviews while increasing the efficiency of our clinical trials,” said Steve Bandak, Chief Medical Officer at Biotie Therapies Inc., a customer of Patient Profiles. “At a time when risk-based monitoring is moving from theory to practice, it’s exciting to see Patient Profiles join such an innovative organization as Medidata, enabling them to further improve the way the industry conducts clinical research.”
Hey, check out all the engineering jobs. Post your resume today!
